Skip to main content

Table 1 Clinical characteristics of the cohort

From: Systemic and central nervous system metabolic alterations in Alzheimer’s disease

Clinical characteristics

AD (n = 40)

Control (n = 34)

P valuea

Female, n (%)

24 (60.00)

23 (67.65)

0.6098

BMI, kg/m2, mean ± SD

23.83 ± 3.06

24.60 ± 4.01

0.3637

Age, year, mean ± SD

74.88 ± 6.38

65.35 ± 6.17

< 0.0001

Cognitive function

 MMSE, mean ± SD

24.40 ± 4.15

28.71 ± 1.29

< 0.0001

 CDR, mean ± SD

0.65 ± 0.30

0.00 ± 0.00

< 0.0001

AD CSF biomarkers

 Aβ1–42, pg/ml, mean ± SD

556.22 ± 115.39

979.12 ± 164.38

< 0.0001

 Tau, pg/ml, mean ± SD

715.70 ± 300.05

196.18 ± 59.72

< 0.0001

 pTau-181, pg/ml, mean ± SD

91.95 ± 23.84

42.91 ± 10.51

< 0.0001

Biochemical measures

 ApoEε4, n (%ε4)

26 (65.00)

6 (17.64)

< 0.0001

 Qalb, mean ± SD

6.69 ± 3.76

5.27 ± 1.82

0.0474

  1. aP value represents result of t-test comparing AD and control group for continuous variables and chi-square test for categorical variables (male/female frequency and ApoEε4 distribution). MMSE Mini-Mental State Exam, CDR Clinical Dementia Rate, Qalb quotient albumin or plasma/CSF albumin ratio